PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Perioperační management pacientů léčených glifloziny | 167 / Anest intenziv Med. 2024;35(3):162-167 / ANESTEZIOLOGIE A INTENZIVNÍ MEDICÍNA www.aimjournal.cz 27. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. PMID: 33200891. 28. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al; SOLOIST‑WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. PMID: 33200892. 29. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium‑Glucose Cotransporter-2 Inhibitors – Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022 Sep;28(9):884-888. doi: 10.1016/j.eprac.2022. 06. 006. Epub 2022 Jun 23. PMID: 35753675. 30. Iwasaki Y, Sasabuchi Y, Horikita S, Furukawa T, Shiotsuka J, Lefor AK, et al. The effect of preoperative sodium‑glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study. BMC Endocr Disord. 2022 Aug 20;22(1):209. doi: 10.1186/s12902-022-01126-z. PMID: 35987618; PMCID: PMC9392326. 31. Steinhorn B, Wiener‑Kronish J. Dose‑dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single‑centre retrospective analysis. Br J Anaesth. 2023 Oct;131(4):682-686. doi: 10.1016/j.bja.2023. 06. 063. Epub 2023 Aug 2. Erratum in: Br J Anaesth. 2024 Apr;132(4):829. PMID: 37541949. 32. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3077-3087. doi: 10.1210/jc.2019-00139. PMID: 30835263. 33. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double‑blind, placebo‑controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21. PMID: 34302745; PMCID: PMC8294807. 34. Sitina M, Lukes M, Sramek V. Empagliflozin‑associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocr Disord. 2023;23(1):81. doi:10.1186/ s12902-023-01339-w. 35. FDA approves label changes to SGLT2 inhibitors regarding temporary discontinuation of medication before scheduled surgery. https://www.fda.gov/drugs/drug‑safety‑and‑availability/ fda‑revises‑labels‑sglt2-inhibitors‑diabetes‑include‑warnings‑about‑too‑much‑acid‑blood ‑and‑serious. Accessed March 23, 2020. 36. BOMSS Patient Safety committee Alert on the use of Gliflozins. https://bomss.org/ clinical‑resources/ March 2022. 37. Peri‑Procedure Management of Patients on Sodium‑glucose cotransporter-2 (SGLT2) Inhibitors. Published online December 2023. https://www.mdanderson.org/content/ dam/mdanderson/documents/for‑physicians/algorithms/clinical‑management/clin ‑management‑mgmt‑sglt2-web‑algorithm.pdf. 38. Selwyn J, Pichardo‑Lowden AR. Managing Hospitalized Patients Taking SGLT2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis. Diabetology. 2023;4(1):86-92. doi:10.3390/diabetology4010010. 39. Raiten JM, Morlok A, D’Ambrosia S, Ruggero MA, Flood J. Perioperative Management of Patients Receiving Sodium‑Glucose Cotransporter 2 Inhibitors: Development of a Clinical Guideline at a Large Academic Medical Center. J Cardiothorac Vasc Anesth. 2024;38(1):5766. doi:10.1053/j.jvca.2023. 10. 011. 40. Khunti K, Aroda VR, Bhatt DL, Bozkurt B, Buse JB, Heerspink HL, et al. Re‑examining the widespread policy of stopping sodium‑glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes Obes Metab. 2022 Nov;24(11):2071-2080. doi: 10.1111/dom.14805. Epub 2022 Aug 4. PMID: 35801339. 41. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al; on behalf of the American Diabetes Association. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S267-S278. doi: 10.2337/dc23-S016. PMID: 36507644; PMCID: PMC9810470. 42. Guideline for Perioperative Care for People with Diabetes Mellitus Undergoing Elective and Emergency Surgery. Published online October 2023. https://www.cpoc.org.uk/ sites/cpoc/files/documents/2024-03/CPOC‑DiabetesGuideline2023.pdf. 43. Crowley K, Scanaill PÓ, Hermanides J, Buggy DJ. Current practice in the perioperative management of patients with diabetes mellitus: a narrative review. Br J Anaesth. 2023;131(2):242252. doi:10.1016/j.bja.2023. 02. 039. 44. NSW Agency for Clinical Innovation. Use of SGLT2‑inhibitors for type 2 diabetes in acute inpatient care: Clinical practice guide. Sydney: ACI; 2023. https://aci.health.nsw.gov.au/__data/assets/ pdf_file/0010/825085/ACI‑Use‑of‑SGLT2-inhibitor‑medicines‑for‑people‑with‑diabetes.pdf. 45. Guidelines of Australian diabetes society. https://www.diabetessociety.com.au/wp ‑content/uploads/2023/05/ADS‑ADEA‑ANZCA‑NZSSD_DKA_SGLT2i_Alert_Ver‑May-2023.pdf. 46. Milder DA, Milder TY, Kam PCA. Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations. Anaesthesia. 2018;73(8):1008-1018. doi:10.1111/ anae.14251. 47. Seki H, Ideno S, Shiga T, Watanabe H, Ono M, Motoyasu A, et al. Sodium‑glucose cotransporter 2 inhibitor‑associated perioperative ketoacidosis: a systematic review of case reports. J Anesth. 2023 Jun;37(3):465-473. doi: 10.1007/s00540-023-03174-8. Epub 2023 Feb 27. PMID: 36849747; PMCID: PMC10229478. 48. Bobrowski D, Kumar R, Wu PE, Lapointe‑Shaw L. Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy. Clin Case Rep. 2021;9(11):e05057. doi:10.1002/ccr3.5057. 49. Pujara S, Ioachimescu A. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. J Investig Med High Impact Case Rep. 2017;5(2):2324709617710040. doi:10.1177/2324709617710040. 50. Bonanni FB, Fei P, Fitzpatrick LL. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2016;12(1):e11-12. doi:10.1016/j.soard.2015. 08. 502. 51. Scheen AJ. Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance. Diabetes Metab. 2023;49(4):101453. doi:10.1016/j.diabet.2023.101453. 52. Meyer EJ, Mignone E, Hade A, Thiruvenkatarajan V, Bryant RV, Jesudason D. Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium‑Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy. Diabetes Care. 2020;43(11):e181-e184. doi:10.2337/dc20-1244. 53. Hamblin PS, Wong R, Ekinci EI, Sztal‑Mazer S, Balachandran S, Frydman A, et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross‑Sectional Study With Implications for SGLT2 Inhibitor‑Treated Type 2 Diabetes. Diabetes Care. 2021 Jun;44(6):e124-e126. doi: 10.2337/dc21-0256. Epub 2021 Apr 25. PMID: 33896795; PMCID: PMC8247528. 54. Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights Into the Recognition and Management of SGLT2-Inhibitor‑Associated Ketoacidosis: It’s Not Just Euglycemic Diabetic Ketoacidosis. Can J Diabetes. 2017;41(5):499-503. doi:10.1016/j.jcjd.2017. 05. 004.
RkJQdWJsaXNoZXIy NDA4Mjc=